Xalud
is a New York-based biotechnology firm that develops non-viral gene therapies for the treatment of inflammatory diseases... Read moreXalud
is a New York-based biotechnology firm that develops non-viral gene therapies for the treatment of inflammatory diseases... Read more
News
Mar 20, 2023
GlobeNewswire
Press Release: Xalud : Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress
Jun 06, 2022
GlobalNewswire
Press Release: Xalud : Xalud Therapeutics CEO to Participate in Two Gene Therapy Focused Panels at BIO International Convention 2022
Mar 02, 2022
FirstWord Pharma
Xalud: Xalud Therapeutics Doses First Patient in Phase 2a Trial of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain
Dec 17, 2021
MarketScreener
Xalud: Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee
Dec 17, 2021
FirstWord PHARMA
Xalud: Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee
Aug 27, 2021
BioCentury
Xalud: With non-viral gene therapy in clinic, PBM-backed Xalud banks $30M series C
Jul 13, 2021
Business Wire
Press Release: Xalud Therapeutics : Xalud Therapeutics Announces the Expansion of Its Strategic Advisors
May 20, 2021
Business Wire
Press Release: Xalud : Xalud Therapeutics' Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas
May 18, 2021
sec
Xalud Therapeutics: Xalud Therapeutics Received $18.2M in Venture Round Funding
May 12, 2021
The Business Journals: New York
Xalud: Xalud Therapeutics fills COO, CTO, other key leadership positions
Xalud Competitors
1
2
3
4
5
6
7
8
9
10